Tadalafil
Highest phase reached
Approved
Drug type
Small molecule
First approval year
2002
- First approval year
- 2002
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Tadalafil
- Molecular weight
- 389.41
- Structure (SMILES)
- CN1CC(=O)N2[C@H](c3ccc4c(c3)OCO4)c3[nH]c4ccccc4c3C[C@@H]2C1=O
- adcirca
- Adcirca
- Adcirca (previously tadalafil lilly)
- adcirca previously tadalafil lilly
- chewtadzy
- Chewtadzy
- cialis
- Cialis
- tadalafil component of entadfi
- Tadalafil component of entadfi
- tadalafil component of opsynvi
- Tadalafil component of opsynvi
- tadalafil lilly
- Tadalafil lilly
- tadalafil mylan
- Tadalafil mylan
- tadliq
- Tadliq
- Talmanco (previously tadalafil generics)
- talmanco previously tadalafil generics
- 5 mg tadalafil
- 5 mg Tadalafil
- chewtadzy
- Chewtadzy
- Cialis
- CIALIS
- Cialis (Tadalafil)
- Cialis 5Mg Tablet
- entadfi component tadalafil
- Entadfi component tadalafil
- ic 351
- IC-351
- ic351
- IC351
- ly 450190
- LY-450190
- ly450190
- LY450190
- nsc 750236
- nsc 759172
- NSC-750236
- NSC-759172
- opsynvi component tadalafil
- OPSYNVI COMPONENT TADALAFIL
- PDE5 inhibitor (tadalafil)
And 50 more, listed on the interactive page.
- ATC classification codes
- G04BE08
Sources for recorded values
- CAS registry numbers
- 171596-29-5
- ChEMBL ID
- CHEMBL779
- InChIKey
- WOXKDUGGOYFFRN-IIBYNOLFSA-N
- PubChem compound IDs
- 110635
- RxNorm IDs (RxCUI)
- 358263
- FDA ingredient codes (UNII)
- 742SXX0ICT
- Applicant
- LILLY
- Approval date
- 21 Nov 2003
- Application number
- NDA021368
- Status
- Authorised
- Status date
- 12 Nov 2002
- Authorisation date
- 12 Nov 2002
- Approved indications
- Treatment of erectile dysfunction. In order for tadalafil to be effective, sexual stimulation is required. Cialis is not indicated for use by women.
- Product number
- EMEA/H/C/000436
- Authorisation holder
- Eli Lilly Nederland B.V.
- Priority medicines scheme
- No
- Generic
- No
- Biosimilar
- No
- Generic medicines
- 2
- Biosimilar medicines
- 0
- Advanced therapy
- No
- Conditional approval
- No
- Additional monitoring
- No
- Accelerated assessment
- No
- Exceptional circumstances
- No
Therapeutic areas
- Erectile Dysfunction
European medicines record
- Patents
- 4
- Designations
- 1
- Earliest recorded loss of exclusivity
- 24 Dec 2038
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- Pharmacology name
- tadalafil
- Type
- Synthetic organic
- Drug name stem
- -afil
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- phosphodiesterase 5A
- Gene symbol
- PDE5A
- Protein identifier
- O76074
- Median affinity
- 8.52
- Affinity units
- pIC50
- Primary target
- Yes
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- phosphodiesterase 11A
- Gene symbol
- PDE11A
- Protein identifier
- Q9HCR9
- Median affinity
- 6.52
- Affinity units
- pIC50
- Mechanism
- Phosphodiesterase 5A inhibitor
- Action type
- Inhibitor
- Target
- cGMP-specific 3',5'-cyclic phosphodiesterase
- Protein identifier
- O76074
Open Targets mechanisms
- Mechanism
- Phosphodiesterase 5A inhibitor
- Action type
- Inhibitor
- Target
- cGMP-specific 3',5'-cyclic phosphodiesterase
DrugCentral mechanisms
- Action type
- Inhibitor
- Gene symbol
- PDE5A
- Protein identifier
- O76074
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Carcinoma, Squamous Cell
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000181
- Subject identifier
- D002294
- Condition
- Prostatic Hyperplasia
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000284
- Subject identifier
- D011470
- Condition
- Heart Failure
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000373
- Subject identifier
- D006333
- Condition
- Glioblastoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000519
- Subject identifier
- D005909
- Condition
- Hypertension
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000537
- Subject identifier
- D006973
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Stroke
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000712
- Subject identifier
- D020521
- Condition
- Scleroderma, Systemic
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000717
- Subject identifier
- D012595
- Condition
- Obesity
- Highest recorded phase
- 2
- Condition identifier
- EFO:0001073
- Subject identifier
- D009765
- Condition
- Pulmonary Arterial Hypertension
- Highest recorded phase
- 4
- Condition identifier
- EFO:0001361
- Subject identifier
- D000081029
- Condition
- Hypertension, Pulmonary
- Highest recorded phase
- 4
- Condition identifier
- EFO:0001361
- Subject identifier
- D006976
- Condition
- Multiple Myeloma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0001378
- Subject identifier
- D009101
- Condition
- Astrocytoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0002499
- Subject identifier
- D001254
- Condition
- Insulin Resistance
- Highest recorded phase
- 3
- Condition identifier
- EFO:0002614
- Subject identifier
- D007333
- Condition
- Pancreatic Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0002618
- Subject identifier
- D010190
- Condition
- Carcinoma, Non-Small-Cell Lung
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003060
- Subject identifier
- D002289
- Condition
- Cushing Syndrome
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003099
- Subject identifier
- D003480
- Condition
- Erectile Dysfunction
- Highest recorded phase
- 4
- Condition identifier
- EFO:0004234
- Subject identifier
- D007172
- Condition
- Lung Diseases, Interstitial
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004244
- Subject identifier
- D017563
- Condition
- Head and Neck Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0004284
- Subject identifier
- D006258
- Condition
- Sexual Dysfunction, Physiological
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004714
- Subject identifier
- D012735
- Condition
- Dementia, Vascular
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004718
- Subject identifier
- D015140
- Condition
- Head and Neck Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0006859
- Subject identifier
- D006258
- Condition
- Eisenmenger Complex
- Highest recorded phase
- 2
- Condition identifier
- EFO:0009200
- Subject identifier
- D004541
- Condition
- Premature Ejaculation
- Highest recorded phase
- 3
- Condition identifier
- EFO:0803321
- Subject identifier
- D061686
And 14 more, listed on the interactive page.
- Condition identifier
- EFO_0000181
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000195
- Condition identifier
- EFO_0000284
- Condition identifier
- EFO_0000341
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000519
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000537
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000616
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000717
- Highest recorded phase
- 2
- Condition identifier
- EFO_0001073
- Highest recorded phase
- 2
- Condition identifier
- EFO_0001361
- Condition identifier
- EFO_0002499
- Highest recorded phase
- 1
- Condition identifier
- EFO_0002503
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003099
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003901
- Condition identifier
- EFO_0003901
- Highest recorded phase
- 4
- Condition identifier
- EFO_0004234
- Condition identifier
- EFO_0004244
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004714
- Condition identifier
- EFO_0004718
- Highest recorded phase
- 2
- Condition identifier
- EFO_0006859
- Condition identifier
- EFO_0008008
- Condition identifier
- EFO_0008008
- Highest recorded phase
- 3
- Condition identifier
- EFO_0008493
- Highest recorded phase
- 2
- Condition identifier
- EFO_0009200
- Highest recorded phase
- 2
- Condition identifier
- EFO_1000653
And 63 more, listed on the interactive page.
- Event
- back pain
- Reports
- 405
- Reporting signal score
- 221.711
- Event
- chest pain
- Reports
- 211
- Reporting signal score
- 90.3085
- Event
- cyanopsia
- Reports
- 29
- Reporting signal score
- 112.711
- Event
- dyspnoea
- Reports
- 1,073
- Reporting signal score
- 565.848
- Event
- dyspnoea exertional
- Reports
- 185
- Reporting signal score
- 217.793
- Event
- fluid retention
- Reports
- 288
- Reporting signal score
- 427
- Event
- flushing
- Reports
- 309
- Reporting signal score
- 301.316
- Event
- headache
- Reports
- 1,223
- Reporting signal score
- 762.358
- Event
- hospitalisation
- Reports
- 274
- Reporting signal score
- 139.639
- Event
- hypotension
- Reports
- 494
- Reporting signal score
- 238.929
- Event
- myalgia
- Reports
- 230
- Reporting signal score
- 120.311
- Event
- nasal congestion
- Reports
- 213
- Reporting signal score
- 257.958
- Event
- optic ischaemic neuropathy
- Reports
- 83
- Reporting signal score
- 220.04
- Event
- oxygen saturation decreased
- Reports
- 195
- Reporting signal score
- 181.892
- Event
- pain in jaw
- Reports
- 192
- Reporting signal score
- 262.547
- Event
- priapism
- Reports
- 79
- Reporting signal score
- 160.799
- Event
- pulmonary arterial hypertension
- Reports
- 255
- Reporting signal score
- 625.75
- Event
- pulmonary arterial pressure increased
- Reports
- 64
- Reporting signal score
- 186.281
- Event
- pulmonary hypertension
- Reports
- 237
- Reporting signal score
- 460.812
- Event
- pulmonary oedema
- Reports
- 151
- Reporting signal score
- 143.983
- Event
- right ventricular failure
- Reports
- 151
- Reporting signal score
- 396.04
- Event
- syncope
- Reports
- 260
- Reporting signal score
- 136.462
- Event
- vision blurred
- Reports
- 269
- Reporting signal score
- 173.793
- NCT00050609
- NCT00125918
- NCT01324999
- NCT00157326
- NCT00174486
- NCT00422578
- NCT00422734
- NCT00547092
- NCT00547183
- NCT00547287
- NCT00547352
- NCT00547417
- NCT00547495
- NCT00547508
- NCT00547573
- NCT00547599
- NCT00215631
- NCT00333281
- NCT00334477
- NCT00381732
- NCT00382135
- NCT00421083
- NCT00644956
- NCT00663130
- NCT00668109
And 87 more, listed on the interactive page.
- Dose
- 5 mg, 10 mg, 20 mg, 2.5 mg, 5 mg
- How often
- As needed, once daily, approximately same time every day, up to 26 weeks, every 48 hours, every 72 hours, not recommended
- Do not split tablets
- Take without regard to food
- Hydrogen bond acceptors
- 4
- Hydrogen bond donors
- 1
- Polar surface area
- 74.87
- Calculated partition coefficient (ALogP)
- 2.21
- Calculated partition coefficient (XLogP)
- 2.3
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 1
- Heavy atoms
- 29
- Molecular formula
- C22H19N3O4
- Monoisotopic mass
- 389.13755610
- Natural product
- Yes
- 0002-4462
- 0002-4463
- 0002-4464
- 0480-2309
- 0480-2310
- 0480-9277
- 13668-565
- 13668-566
- 13668-567
- 13668-568
- 13668-581
- 16714-074
- 16714-075
- 16714-076
- 16714-077
- 16729-369
- 16729-370
- 16729-371
- 16729-372
- 24979-727
- 24979-728
- 24979-729
- 24979-730
- 27241-111
- 27241-112
And 228 more, listed on the interactive page.
- Recorded assays
- 1,893
- Active assays
- 119
- Confirmatory
- Other
- Screening
- Vasodilator Agents
- Phosphodiesterase 5 Inhibitors
- Urological Agents
These details could not be displayed.
Related records
Trials (249)
- A 48-week Study of the Effect of Dual Therapy (Inhaled Treprostinil and Tadafafil) Versus Monotherapy (Tadalafil).
- A Bioavailability Study of LY2452473 and Tadalafil
- A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis
- A Multicentre, Prospective, Open-label, Non-comparative Study
- A Pharmacokinetic Drug-Drug Interaction (DDI) Study Between Sitaxsentan And Sildenafil, And Between Sitaxsentan And Tadalafil After Multiple Doses
- A Pharmacokinetics Study for Pediatric Participants With Pulmonary Arterial Hypertension
- A Phase 1 Relative Bioavailability Study of Ambrisentan and Tadalfil Fixed Dose Combination Tablets in Healthy Subjects
- A Phase II Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract
- A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma
- A Randomized, Open-Label, Crossover, Multicenter, Single Dose Comparator Study Evaluating Onset Of Penile Rigidity In Men With Erectile Dysfunction Who Are Treated With Sildenafil And Tadalafil
- A Single Dose Randomized Five-Way Crossover Pharmacokinetics (PK) Study of Tadalafil Semi-Chewable (Gummy) Formulations in Healthy Volunteers
- A Study for Patients With Erectile Dysfunction to Test Whether Tadalafil Taken Once a Day Can Better Improve Psychological Outcomes.
- A Study in Benign Prostatic Hyperplasia
- A Study in Erectile Dysfunction
- A Study in Erectile Dysfunction
- A Study in Patients With Erectile Dysfunction
- A Study in the Treatment of Erectile Dysfunction and Benign Prostate Hyperplasia
- A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
- A Study of Fixed Dose Combination of Macitentan/Tadalafil (10 mg/20 mg) Compared to the Reference Free Combination of Macitentan and Tadalafil in Healthy Adult Participants
- A Study of LY2623091 in Healthy Participants
Approved for (4)
- Benign prostatic hyperplasia
- Erectile dysfunction
- Pulmonary arterial hypertension
- Pulmonary hypertension
In development for (34)
- Alzheimer disease Phase 2
- Anaplastic astrocytoma Phase 1
- Cancer Phase 1
- Chronic obstructive pulmonary disease Phase 3
- Congenital heart disease Phase 3
- Congestive heart failure Phase 1
- Cushing syndrome Phase 2
- Duchenne muscular dystrophy Phase 3
- Eisenmenger syndrome Phase 2
- Essential hypertension Phase 2
- Exocrine pancreatic carcinoma Phase 2
- Gastroparesis Phase 2
- Glioblastoma Phase 1
- Glucose intolerance Phase 3
- Head and neck cancer Phase 1
- Head and neck squamous cell carcinoma Phase 2
- Hypertensive disorder Phase 2
- Interstitial lung disease Phase 3
- Major depressive disorder Phase 1
- Muscular dystrophy Early phase 1
Targets (1)
- PDE5A Phosphodiesterase 5A inhibitor